Login to Your Account



Financings Roundup


Wednesday, March 6, 2013
• TauRx Pharmaceuticals Ltd., of Singapore, received an equity investment of $10.5 million from Dundee Corp., of Toronto, to support Phase III trials of LMTX for Alzheimer's disease and behavioral-variant fronto-temporal dementia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription